System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Arun J Sanyal is an expert in Hepatology at Virginia Commonwealth University (United States). As of October 2026, ScienceLeadR ranks Arun J Sanyal in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Liver Cirrhosis. Arun J Sanyal has authored 1,373 publications, the most recent in 2026, and is an investigator in 87 clinical trials, 4 of them ongoing. SLR score: 8,372 (community average: 125). How the SLR is computed.

LeadR Profile

Arun J Sanyal Virginia Commonwealth University United States
8 372 ScienceLeadR Reputation 8372

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Biochemistry - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026
Source: PubMed

Virginia Commonwealth University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1373

Citations

Citations: 144 772 1st author: 109 Last author: 435 Unique author: 67

Main journals

J Hepatol 214
Gastroenterology 159
Hepatology 135
Clin Gastroenterol Hepatol 62
Am J Gastroenterol 59

Best Journals

J Hepatol 57
N Engl J Med 22
Nat Med 18

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH).
PMID 42892346 — liver diseases, diabetes mellitus, safety, fibrosis, non-alcoholic fatty liver disease, liver, histology, diabetes mellitus, type 2		JHEP Rep20260
Training the next generation of hepatologists for the cardiovascular-kidney-metabolic era.
PMID 42888296 — kidney, gastroenterologists		Nat Rev Gastroenterol Hepatol Top journal20260
Global Sociodemographic Disparities in the Severity of Alcohol-Associated Hepatitis.
PMID 42858793 — liver diseases, hepatitis, alcoholic, mortality, alcoholism, liver diseases, alcoholic, education, hepatitis		Ann Hepatol20260
Therapies for alcohol use disorder in alcohol-associated hepatitis clinical trials: Integrated trial design with a composite clinical outcome as the primary endpoint.
PMID 42804611 — liver diseases, alcoholism, adrenal cortex hormones, therapeutics, motivational interviewing, hepatitis, alcohol abstinence		Hepatology20260
Baseline characteristics of a prospective, multi-center study on the natural history of compensated cirrhosis: the Liver Cirrhosis Network.
PMID 42754973 — natural history, liver cirrhosis, multiple chronic conditions, liver, history		Am J Gastroenterol20260

Clinical Studies 87

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11 Study Chair: 1

By phase:

Phase 2 40
Phase 3 23
N/A 19
Phase 1 3
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 71
Terminated 8
Active not recruiting 4
Recruiting 3
Withdrawn 1

By type:

Interventional 74
Observational 13

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 7
multicentric5to9 7
multicentricup10 62

Main Topics

Cohort/Consortium Investigators 11

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229 — liver diseases, hepatitis c, rosuvastatin calcium, safety, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, liver, alcoholics, liver cirrhosis, alcoholic, calcium, therapeutics, hepatitis b, fatty liver, random allocation, fatty liver, alcoholic, hepatitis		Phase 2Recruiting2023
Liver Cirrhosis Network Cohort Study
NCT05740358 — liver diseases, hepatitis, autoimmune, hepatitis c, cholangitis, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, cohort studies, liver, alcoholics, liver cirrhosis, alcoholic, cholangitis, sclerosing, hepatitis b, fatty liver, liver cirrhosis, biliary, fatty liver, alcoholic, hepatitis		N/AActive not recruiting2022
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728 — liver diseases, safety, fibrosis, non-alcoholic fatty liver disease, liver, alcoholics, peroxisomes, therapeutics, fatty liver, fatty liver, alcoholic, peroxisome proliferator-activated receptors		Phase 3Active not recruiting2021
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS